Anne Edwards

Revolution Medicines · company speakers →

shared data on RMC-5127, a KRAS inhibitor that selectively targets the activated form of mutant KRAS G12V.

Is this you? Claim this profile →

No public contact links on file.

Speaking history

AACR Drug Discovery and Development (AACR D3)

21 July 2026 Boston, United States “RMC-5127: KRAS G12V Inhibitor”

Sourcing speakers for your event?

Browse the speaker directory →